Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2024 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2024 Earnings Call Transcript February 27, 2025Aurinia Pharmaceuticals Inc. misses on earnings expectations.
Aurinia Pharmaceuticals Inc. (AUPH)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Diamond Hill Capital Ric Dillon | 70,099 | $563,596 | 0% | |
| 2. | 0 | $0 | 0% | ||
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 0 | $0 | 0% | |
| 4. | Bailard Inc Thomas Bailard | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.09 | 100,000 | 10,029,500 | 2025-03-04 | Filing | ||
| $7.92 | 500,000 | 9,929,500 | 2025-03-04 | Filing | ||
| $8.00 | 148,038 | 9,429,500 | 2025-03-04 | Filing | ||
| $8.02 | 351,962 | 9,281,462 | 2025-03-03 | Filing | ||
| $7.97 | 100,720 | 8,929,500 | 2025-03-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.23 | 8,305 | Officer | 153,484 | 2025-03-07 | Filing | |
| $7.92 | 164,947 | Officer, Director | 1,788,945 | 2025-03-04 | Filing | |
| $8.00 | 195,593 | Officer, Director | 1,953,892 | 2025-03-03 | Filing | |
| $8.00 | 12,239 | Officer | 161,789 | 2025-03-03 | Filing | |
| $7.92 | 56,154 | Officer | 577,361 | 2025-03-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,759,388 | $70,425,481 | 0% | |
| 2. | 1,971,806 | $15,853,320 | 0% | |
| 3. | 1,631,482 | $13,117,115 | 0% | |
| 4. | 752,769 | $6,052,263 | 0.06% | |
| 5. | 521,416 | $4,192,185 | 0% |
News See All
10 Best Small-Cap Growth Stocks to Buy Now
On November 4, 2024, Nick Sheridan, Portfolio Manager at Janus Henderson released a report on small-cap stocks exploring how these stocks offer unique growth and diversification opportunities.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2024 Earnings Call Transcript
Operator: Greetings, and welcome to Aurinia Pharmaceuticals Third Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2024 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2024 Earnings Call Transcript August 1, 2024Aurinia Pharmaceuticals Inc. misses on earnings expectations.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.07464, expectations were $-0.17.
11 Oversold Biotech Stocks To Buy Right Now
In this article, we will be taking a look at 11 oversold biotech stocks to buy right now.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2023 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.19 EPS, expectations were $-0.18.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript
Operator: Greetings. Welcome to Aurinia Pharmaceuticals Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
13 Stocks to Buy with Exponential Growth
Optimism was prevailing in the US stock market on October 11 as investors were hopeful that the Federal Reserve won’t take a hawkish stance for the rest of the year amid rising bond yields that are ...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2023 Earnings Call Transcript
Operator: Greetings. And welcome to Aurinia Pharmaceuticals Incorporated Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.